Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

NCT06767514

RecruitingPhase 3

Sponsor: Summit Therapeutics

Conditions: Non-Small Cell Lung Cancer

Interventions: Ivonescimab Injection, Pembrolizumab Injection

Countries: United States, Belgium, Canada, China, France, Germany, Greece, Hungary

Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Age ≥ 18 years old at the time of enrollment
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1
* Expected life expectancy ≥ 3 months
* Metastatic (Stage IV) NSCLC
* Histologically or cytologically confirmed squamous or non-squamous NSCLC
* Tumor demonstrates high PD-L1 expression ( TPS\>50%) based on a 22C3 immunohistochemistry ( IHC) clinical assay approved / cleared by local health authorities.
* At least one measurable noncerebral lesion according to RECIST 1.1
* No prior systemic treatment for metastatic NSCLC.

Exclusion Criteria:

* Histologic or cytopathologic evidence of the presence of small cell lung carcinoma for which first-line approved therapies are indicated. For patients with non-squamous histology, actionable driver mutation testing results are required before randomization.
* Has received any prior therapy for NSCLC in the metastatic setting.
* Concurrent enrollment in another clinical study, unless patient is enrolled in a non-interventional clinical study or is completing survival follow -up.
* Known actionable genomic alterations for which first-line approved therapies are indicated
* Symptomatic CNS metastases, CNS metastasis ≥ 1.5 cm, CNS radiation within 7 days prior to randomization, potential need for CNS radiation within the first cycle, or leptomeningeal disease
* Other prior malignancy (including previously treated NSCLC) unless the patient has undergone curative therapy with no evidence of recurrence of the disease for 3 years prior to randomization
* Active autoimmune or lung disease requiring systemic therapy
* Has pre-existing peripheral neuropathy that is ≥ Grade 2 by CTCAE version 5
* Severe infection within 4 weeks prior to randomization
* Major surgical procedures or serious trauma within 4 weeks prior to randomization
* History of noninfectious pneumonia requiring systemic corticosteroids, or current interstitial lung disease
Locations (274)
  • Chandler, Arizona, United States
  • Phoenix, Arizona, United States
  • Hot Springs, Arkansas, United States
  • Jonesboro, Arkansas, United States
  • Alameda, California, United States
  • Anaheim, California, United States
  • Beverly Hills, California, United States
  • Cerritos, California, United States
  • Los Angeles, California, United States
  • Los Angeles, California, United States
  • Orange, California, United States
  • Oxnard, California, United States
  • San Diego, California, United States
  • Sunnyvale, California, United States
  • Torrance, California, United States
  • Aurora, Colorado, United States
  • Denver, Colorado, United States
  • Grand Junction, Colorado, United States
  • Lone Tree, Colorado, United States
  • Loveland, Colorado, United States
  • Fort Lauderdale, Florida, United States
  • Fort Lauderdale, Florida, United States
  • Jacksonville, Florida, United States
  • Jacksonville Beach, Florida, United States
  • North Venice, Florida, United States
  • Orlando, Florida, United States
  • Pensacola, Florida, United States
  • Plantation, Florida, United States
  • Tallahassee, Florida, United States
  • Tamarac, Florida, United States
  • + 244 more on CT.gov